Compare Clorox Co (CLX) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Clorox Co vs GSK plc — how do they compare? Clorox Co trades at $96 (market cap $11.46B), while GSK plc trades at $51.46 (market cap $101.55B). The key difference: GSK plc is far larger — about 8.9× Clorox Co's market cap, and Clorox Co pays the higher dividend (5.23%). Which is the better fit depends on your goals.
| CLX | GSK | |
|---|---|---|
Market Cap | $11.46B | $101.55B |
Sector | Consumer Staples | Health |
52-Week High | $131.43 | $61.18 |
52-Week Low | $86.12 | $36.20 |
Enterprise Value | $14.76B | $122.16B |
Dividend Yield | 5.23% | 3.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CLX trades at $95.05, down 1.56% on the day, with technical indicators showing a bearish trend. The company reported strong Q1 2026 earnings beat with EPS of $1.64 versus $1.55 expected, though revenue trends remain flat. Recent corporate developments include a simplified operating structure announcement and CEO transition for health reasons. The stock offers a 5%+ dividend yield with recent H1-26 dividend of $1.24 payable May 2026.
CLX presents a mixed outlook with attractive dividend income but faces growth challenges. The 8.7% upside to consensus price target of $103.38 suggests moderate potential, though high P/B ratio of 41.4 and declining revenue projections for 2026 warrant caution. Key risks include execution of new operating structure and competitive pressures in consumer staples.
GSK trades at $52.29, down 0.93% with neutral technical signals. The company shows strong fundamentals with Q1 2026 EPS beating expectations at $1.24 versus $1.16 forecast. Recent FDA approvals for Utebzi and positive Jemperli trial results highlight pipeline strength. Valuation metrics appear reasonable with P/E of 13.94 and ROE of 36.42%.
GSK presents a balanced investment case with solid profitability and promising drug pipeline offset by mixed analyst sentiment and competitive pressures. The stock offers income potential with 3.46% dividend yield but faces execution risks in drug development and market competition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Clorox Co
With a history dating back more than 100 years, Clorox now plays in a variety of categories across the consumer products space, including cleaning supplies, laundry care, trash bags, cat litter, charcoal, food dressings, water-filtration products, and natural personal-care products. Beyond its namesake brand, the firm's portfolio includes Liquid-Plumr, Pine-Sol, S.O.S, Tilex, Kingsford, Fresh Step, Glad, Hidden Valley, KC Masterpiece, Brita, and Burt's Bees. Just shy of 85% of Clorox's sales stem from its home turf.
Read more on CLX →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
